Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells

被引：9

作者：

Tang, Xiaolong ^{[1
]}

Xie, Chunmei ^{[2
]}

Jiang, Zhenyou ^{[3
,4
]}

Li, Amin ^{[1
]}

Cai, Shiyu ^{[1
]}

Hou, Changhao ^{[1
]}

Wang, Jian ^{[1
]}

Liang, Yong ^{[5
,6
]}

Ma, Dong ^{[7
]}

机构：

[1] Anhui Univ Sci & Technol, Med Coll, Huainan, Peoples R China

[2] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Dept Lab Med, Guangzhou, Guangdong, Peoples R China

[3] Jinan Univ, Dept Microbiol, Guangzhou, Guangdong, Peoples R China

[4] Jinan Univ, Dept Immunol, Guangzhou, Guangdong, Peoples R China

[5] Xuzhou Med Coll, Huaian Hosp, Huaian, Peoples R China

[6] Huaian Second Hosp, Huaian, Peoples R China

[7] Jinan Univ, Dept Biomed Engn, Guangdong Higher Educ Inst, Key Lab Biomat, Guangzhou, Guangdong, Peoples R China

来源：

ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY | 2018年 / 46卷

基金：

中国国家自然科学基金;

关键词：

Non-Hodgkin's lymphoma; mTOR; signal pathways; rituximab; nanoparticles; TOR serine-threonine kinases; AZD-2014; NON-HODGKINS-LYMPHOMA; PRECLINICAL EVALUATION; INHIBITOR; MTOR; METABOLISM; ACTIVATION; INITIATION; APOPTOSIS; PATHWAYS; GROWTH;

D O I：

10.1080/21691401.2018.1478844

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The mTOR signal pathway is often highly activated in B-cell non-Hodgkin's lymphoma (NHL) and promotes cancer progression and chemo-resistance. Therefore, the pathways of mTOR are an important target for drug development in this disease. In the current study, we developed a rituximab (anti-CD20)-modified mTOR inhibitor, AZD-2014, loaded into nanoparticles (Ab-NPs-AZD-2014) for trial of its anti-NHL effect. In a cultured NHL cell line, Ab-NPs-AZD-2014 inhibited cancer cell growth, induced cell apoptosis, and blocked activation of mTORC1 and mTORC2 in Raji cells. These results indicate that antibody modification and nanomaterial loading of AZD-2014 with anti-CD20 significantly improved efficacy of AZD-2014 against NHL cells. This approach may ultimately deserve testing in therapy against NHL.

引用

页码：1063 / 1073

页数：11

共 34 条

[31] Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas [J].

Zappasodi, Roberta ;

Cavane, Alessandra ;

Iorio, Marilena V. ;

Tortoreto, Monica ;

Guarnotta, Carla ;

Ruggiero, Giusi ;

Piovan, Claudia ;

Magni, Michele ;

Zaffaroni, Nadia ;

Tagliabue, Elda ;

Croce, Carlo M. ;

Zunino, Franco ;

Gianni, Alessandro M. ;

Di Nicola, Massimo .

INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (09) :2034-2045

[32] Composites of Polymer Hydrogels and Nanoparticulate Systems for Biomedical and Pharmaceutical Applications [J].

Zhao, Fuli ;

Yao, Dan ;

Guo, Ruiwei ;

Deng, Liandong ;

Dong, Anjie ;

Zhang, Jianhua .

NANOMATERIALS, 2015, 5 (04) :2054-2130

[33] Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma [J].

Zheng, Bing ;

Mao, Jia-Hui ;

Qian, Lin ;

Zhu, Hua ;

Gu, Dong-hua ;

Pan, Xiao-dong ;

Yi, Fang ;

Ji, Dong-mei .

CANCER LETTERS, 2015, 357 (02) :468-475

[34] Mastocarcinoma therapy synergistically promoted by lysosome dependent apoptosis specifically evoked by 5-Fu@nanogel system with passive targeting and pH activatable dual function [J].

Zhu, Xiandi ;

Sun, Yn ;

Chen, Di ;

Li, Jingfeng ;

Dong, Xia ;

Wang, Jie ;

Chen, Huaiwen ;

Wang, Ying ;

Zhang, Fulei ;

Dai, Jinaxin ;

Pirraco, Rogerio P. ;

Guo, Shangjing ;

Marques, Alexandra P. ;

Reis, Rui L. ;

Li, Wei .

JOURNAL OF CONTROLLED RELEASE, 2017, 254 :107-118

← 1 2 3 4 →